Holen Sie sich die Stockscreener-App
0.9609
1.27%
0.0085
Schlusskurs vom Vortag:
$0.9524
Offen:
$0.97
24-Stunden-Volumen:
48,387
Relative Volume:
0.33
Marktkapitalisierung:
$40.73M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.37M
KGV:
-0.6682
EPS:
-1.438
Netto-Cashflow:
$-4.23M
1W Leistung:
+3.50%
1M Leistung:
-2.77%
6M Leistung:
-37.37%
1J Leistung:
-20.94%
1-Tages-Spanne:
$0.9504
$0.97
1-Wochen-Bereich:
$0.9327
$0.9947
52-Wochen-Spanne:
$0.90
$2.45
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Firmenname
Mira Pharmaceuticals Inc
Sektor
Telefon
813-369-5150
Adresse
1200 BRICKELL AVENUE, MIAMI
Compare MIRA vs LLY, JNJ, ABBV, NVS, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
0.9692 | 40.02M | 0 | -31.37M | -4.23M | -1.438 |
LLY
Lilly Eli Co
|
1,107.43 | 979.64B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
230.97 | 549.78B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
231.63 | 382.49B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
149.00 | 280.64B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
115.30 | 281.24B | 65.51B | 8.93B | 14.12B | 3.5532 |
Mira Pharmaceuticals Inc Aktie (MIRA) Neueste Nachrichten
MIRA SEC FilingsMira Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy - ACCESS Newswire
Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Telomir Pharmaceuticals Inc (TELO) Institutional Confidence - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mira Pharmaceuticals Inc (MIRA) Institutional Confidence - TradingKey
Mira Pharmaceuticals Inc (MIRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mira Pharmaceuticals Inc (MIRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mira Pharmaceuticals Inc (MIRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mira Pharmaceuticals Inc (MIRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MIRA Pharmaceuticals submits Phase 2a trial for Ketamir-2 - grafa.com
MIRA Pharmaceuticals submits Phase 2a trial protocol for CIPN By Investing.com - Investing.com South Africa
MIRA Advances Ketamir-2 Into FDA-Accepted Phase 2a Trial - TipRanks
MIRA Pharmaceuticals submits Phase 2a trial protocol for CIPN - Investing.com
Phase 2a CIPN trial protocol for Ketamir-2 accepted, MIRA (NASDAQ: MIRA) - Stock Titan
Chemo nerve damage leaves millions without an approved drug; MIRA plans Ketamir-2 trial - Stock Titan
MIRA PHARMACEUTICALS (MIRA) director granted 50,000 stock options award - Stock Titan
MIRA Pharmaceuticals (MIRA) grants director 50,000 stock options at $0.94 - Stock Titan
MIRA Pharmaceuticals grants director 50,000 stock options | MIRA Insider Trading - Stock Titan
MIRA Pharmaceuticals Inc. (MIRA) Edges Higher: Navigating Key Levels in a Volatile SectorGolden Cross - newsline.com
MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer - The Globe and Mail
MIRA PHARMACEUTICALS (MIRA) CFO Andriy Mushak listed as insider in Form 3 - Stock Titan
Mira Pharmaceuticals appoints Andriy Mushak as fractional CFO By Investing.com - Investing.com Nigeria
Mira Pharmaceuticals appoints Andriy Mushak as fractional CFO - Investing.com
Mira PharmaceuticalsAlan Weichselbaum To Step Down As CFO Effective June 6, 2026SEC Filing - TradingView
MIRA appoints Andriy Mushak as fractional CFO as Alan Weichselbaum departs - TradingView
Mira Pharmaceuticals (NASDAQ: MIRA) hires fractional CFO via LMAM - Stock Titan
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
MIRA Pharmaceuticals Holds Steady at $1.0 as Key Support and Resistance TestedLinear Regression - newsline.com
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 - ACCESS Newswire
MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline - TipRanks
MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1SEC Filing - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) consolidates worldwide exclusive rights to MIRA-55 and SKNY-1 - Stock Titan
Experimental obesity and chronic pain drugs now under MIRA's global control - Stock Titan
MIRA Pharmaceuticals Faces Subdued Sentiment as Stock Dips Toward Key SupportAccumulation Line - newsline.com
MIRA News | MIRA PHARMACEUTICALS INC (NASDAQ:MIRA) - ChartMill
MIRA Pharmaceuticals Inc. (MIRA) Slips 8.66% to $1.05 as Technicals Test Key SupportRevenue Growth Stocks - The Legal Advocate
MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN - Black Hills Pioneer
MIRA Pharmaceuticals Q3 2025 Earnings: EPS Beats Estimates Amid Narrowing Losses; Stock DeclinesEarnings Call Q&A - newsline.com
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide - Investing.com UK
MIRA Pharmaceuticals expands Ketamir-2 license to worldwide By Investing.com - Investing.com Nigeria
MIRA Expands Global Ketamir-2 License for Clinical Development - TipRanks
Mira Pharmaceuticals enters into amendment no 1 to exclusive license agreement with Miralogx - marketscreener.com
MIRA Pharmaceuticals (MIRA) expands Ketamir-2 license to worldwide IP rights - Stock Titan
Experimental oral chemo nerve damage drug gets IP boost in 10 countries - Stock Titan
MIRA Pharmaceuticals Edges Higher, Consolidating Near Key Resistance at $1.04AAII Bearish - newsline.com
MIRA Pharmaceuticals Inc. (MIRA) Nears Support After Marginal DeclineRetracement Entry - The Legal Advocate
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss Lifts SharesEarnings Season Outlook - The Legal Advocate
Finanzdaten der Mira Pharmaceuticals Inc-Aktie (MIRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):